Description of the warning label. by Yulian Ding (5984591)

Subjects:

Flow chart of the study. by Yulian Ding (5984591)

Subjects:

Summary statistics of the sample. by Yulian Ding (5984591)

Subjects:

Product attributes and attribute levels. by Yulian Ding (5984591)

Subjects:

Dataset used in this study. by Yulian Ding (5984591)

Subjects:

Definitions of the variables. by Yulian Ding (5984591)

Subjects:

Networks favouring more connected individuals results in a significant decrease to the likelihood of network recovery. by Adam Lee Miles (14123916)

Aripiprazole significantly decreases phosphorylated Src (Y416) levels in dHL-60 cells. by Courtney A. Swain (15170264)

Supplementation of five Lactobacillus strains affected the colonization of <i>M</i>. <i>pneumoniae</i> and lung injuries. by Huanbing Long (19949784)

The significant decrease in GLT-1 levels observed in the nucleus accumbens of rats that had consumed morphine for fifty-six days was completely reversed by the co-administration of... by María Elena Quintanilla (8068691)

Brain regions with significantly decreased activations for the Raven task are shown in blue. by Morteza Fattahi (15892028)

Distribution of Differentially Expressed Genes (DEGs) in affected biological pathways in βA3ΔG91 lenses relative to WT lenses. by Akosua K. Boateng (21672931)

Subjects:

Manhattan plot for genome-wide association study (GWAS) in a European population with depression. by Xiaomei He (795333)

Subjects:

Correlation between protein abundances and R_5-20 z-score among cases at baseline. Protein abundances, normalized to mean 0 and variance 1, are displayed on the y-axis. (... by Spela Kokelj (8356644)

Subjects:

Age- and sex- specific median yearly incidence (A) and mortality (B) rate of liver cancer per 10⁶ population over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

related to Fig 4. ROS, K+ efflux and cathepsin B do not affect TNFα production in response to eggs. by Madhusoodhanan Suresh Kumar Meena Kumari (20896666)

Crude and age-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and type-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and residence-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Age-adjusted annual percent changes (APC) in incidence (A), mortality (B), and prevalence (C) rates per 100,000 over 2014–2023 for both sexes and sex-specific. by Ayana Ablayeva (22103708)

Subjects: